TA
GILD icon

TMD & Associates’s Gilead Sciences GILD Stock Holding History

TMD & Associates’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-41,623
Closed -$2.98M – 26
2016
Q4 		$2.98M Sell
41,623
-10,296
-20% -$765K 2.59% 17
2016
Q3 		$4.11M Buy
51,919
+6,473
+14% +$526K 3.61% 13
2016
Q2 		$3.79M Buy
45,446
+3,418
+8% +$303K 3.35% 14
2016
Q1 		$3.86M Buy
42,028
+16,940
+68% +$1.53M 3.82% 12
2015
Q4 		$2.54M Buy
+25,088
New +$2.61M 2.33% 14

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

TMD & Associates's GILD Position: Q1 2017 in Review

TMD & Associates sold out of Gilead Sciences (GILD) in Q1 2017, closing a stake of 41,623 shares — an estimated $2.98M sold.

TMD & Associates first reported a position in GILD in Q4 2015 and held it in 5 quarters. The position peaked at $4.11M in Q3 2016. 1,525 funds tracked by Wall St. Rank hold GILD as of Q1 2017.

  • TMD & Associates reported no remaining Gilead Sciences position as of Q1 2017 after selling out during the quarter.
  • TMD & Associates sold 41,623 Gilead Sciences shares in Q1 2017, an estimated $2.98M.
  • TMD & Associates first reported a position in Gilead Sciences in Q4 2015 and held it in 5 quarters.
  • TMD & Associates's Gilead Sciences position peaked at $4.11M in Q3 2016.
  • 1,525 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2017.

Based on TMD & Associates's 13F filing for Q1 2017, filed 26 Apr 2017.